B lymphocyte depletion therapy with rituximab in rheumatoid arthritis

被引：71

作者：

Edwards, JCW ^{[1
]}

Leandro, MJ ^{[1
]}

机构：

[1] UCL, Ctr Rheumatol, London W1T 4NJ, England

来源：

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2004年 / 30卷 / 02期

关键词：

D O I：

10.1016/j.rdc.2004.01.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

B lymphocyte depletion therapy in rheumatoid arthritis can provide major clinical benefits. Widespread use in the future will depend on continued evidence of safety, particularly in the context of long-term use. Rituximab is a highly effective agent, but it may be best used in combination with other agents. Substantial improvement following a single course of therapy has been found to last up to 42 months, and it is reasonable to hope that further development of strategies targeting B cells will extend this toward the original aim of truly long-term remission.

引用

收藏

页码：393 / +

页数：12

相关论文

共 26 条

[11]

Edwards JCW, 2002, ARTHRITIS RHEUM-US, V46, pS197

[12] B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders [J].

Edwards, JCW ;

Leandro, MJ ;

Cambridge, G .

BIOCHEMICAL SOCIETY TRANSACTIONS, 2002, 30 :824-828

[13] HOW IMPORTANT ARE T-CELLS IN CHRONIC RHEUMATOID SYNOVITIS [J].

FIRESTEIN, GS ;

ZVAIFLER, NJ .

ARTHRITIS AND RHEUMATISM, 1990, 33 (06) :768-773

[14] Clinical applications of anti-CD20 antibodies [J].

Gopal, AK ;

Press, OW .

JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1999, 134 (05) :445-450

[15] A prospective study on the incidence of rheumatoid arthritis among people with persistent increase of rheumatoid factor [J].

Halldórsdóttir, HD ;

Jónsson, T ;

Thorsteinsson, J ;

Valdimarsson, H .

ANNALS OF THE RHEUMATIC DISEASES, 2000, 59 (02) :149-151

[16] An open study of B lymphocyte depletion in systemic lupus erythematosus [J].

Leandro, MJ ;

Edwards, JC ;

Cambridge, G ;

Ehrenstein, MR ;

Isenberg, DA .

ARTHRITIS AND RHEUMATISM, 2002, 46 (10) :2673-2677

[17] Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion [J].

Leandro, MJ ;

Edwards, JCW ;

Cambridge, G .

ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (10) :883-888

[18]

MANNIK M, 1985, CLIN RHEUM DIS, V11, P551

[19] How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease [J].

Matsumoto, I ;

Maccioni, M ;

Lee, DM ;

Maurice, M ;

Simmons, B ;

Brenner, M ;

Mathis, D ;

Benoist, C .

NATURE IMMUNOLOGY, 2002, 3 (04) :360-365

[20] Rituximab: perspective on single agent experience, and future directions in combination trials [J].

McLaughlin, P .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 40 (01) :3-16